Interpreting data on inhibitor development from previously untreated patient studies, beware of premature conclusions

Note: Funding Information: K. Fischer has received speaker’s fees from Bayer, Baxter, Biotest, CSL Behring, Biotest Octapharma, Pfizer, NovoNordisk; performed consultancy for Bayer, Baxter, Biogen, CSL-Behring, Freeline, NovoNordisk, Pfizer, Roche and SOBI; and has received research support from Bayer, Pfizer, Baxter, and Novo Nordisk. K Fischer is the epidemiologist for the EUHASS and PedNet registries.